Our Research Approach
We are building Hemab to reimagine care for people living with coagulation disorders who experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. By leveraging our deep understanding of the underlying biology of blood coagulation, we are developing targeted therapies for bleeding and thrombotic disorders like Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and others.
Every Hemab program begins by listening to people who live with their conditions and learning about what they still need.
Lived experiences reveal bleed rates, treatment patterns, and the impact of bleeding disorders on daily life.
Our therapeutic candidates are designed to connect with the body’s natural clotting proteins in a very precise way. This helps protect them from breaking down and lets them build up to levels that can help stop bleeding. When needed, our technology can also help guide these proteins to the site of an injury to support healing.
Time to leapfrog therapeutics is now.
We are building a franchise designed to address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management.
Decades of Treatment Neglect.
For decades, certain bleeding disorders have remained in the shadows as research and innovation focused elsewhere.
At Hemab, we develop therapies that reimagine the treatment of blood coagulation disorders like Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease—conditions where many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches.
Overlooked voices, unmet needs
Every Hemab program starts with the experts who understand these conditions most intimately—the people living with them every day.
Our comprehensive natural history studies reveal what clinical literature often misses: the anxiety of unpredictable bleeding, the careful planning required for everyday activities, and the nuanced impact these conditions have on daily life that may not be fully captured in standard clinical assessments.
Harnessing new possibilities in therapeutics.
Our deep understanding of the underlying biology of blood coagulation enables us to match ideal pharmacological targets with the best suited technologies. We are modality agnostic, adopting multiple validated technologies, when designing our product candidates and programs.
We believe this allows us to develop treatments that can:
• Stabilize essential coagulation proteins from premature breakdown
• Enable these proteins to accumulate to levels that prevent bleeding
• Play a critical role in initiating the coagulation cascade
• Direct these proteins to injury sites where they're needed most
We believe that this approach of utilizing validated modalities and applying them to therapeutic targets with the highest scientific rationale maximizes our probability of success.
Pipeline
We are building a franchise designed to address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management.
Future Pipeline Development
We believe our franchise and patient-focused approach position us to address critical gaps in the treatment of coagulation disorders.
Looking Beyond the Horizon: We're actively researching additional conditions where our approach could address significant unmet needs.
If you have questions about our ongoing clinical trials, please get in touch with our Medical team
Meet the Team
Hemab unites experts in clotting, patient care, and drug development to transform the lives of people with bleeding disorders.
Latest News
